Phase I-II FIH TROP2 ADC Advanced Unresectable/Metastatic Solid Tumors Refractory to Standard Therapies
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types:
i. Ovarian epithelial cancer (Phase I only) ii. Gastric adenocarcinoma (Phase I-II) iii. Pancreatic adenocarcinoma (Phase I-II) iv. Triple negative breast cancer (Phase I only) v. Bladder cancer (Phase I-II)
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced/Metastatic Solid Tumors who are refractory to Available Standard Therapies
- ClinicalTrials.gov Identifier: NCT04152499
- Protocol Number: 19-600
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required